Navigation Links
Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
Date:10/20/2010

FREMONT, Calif., Oct. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection.

The Phase I open-label, dose-escalation study was initiated during the first quarter of 2010 to evaluate the safety, tolerability and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II). Enrollment has been completed, with no dose-limiting toxicities observed, in five of the six cohorts of Stratum I.  Dosing at the highest planned dose level has been initiated in this patient population. Up to 30 NAION patients will be enrolled in Stratum II. In addition to safety and pharmacokinetic assessments, changes in visual acuity and visual field following the administration of QPI-1007 will be measured.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "After escalating to the highest planned dose of QPI-1007 in patients with chronic nerve atrophy, we are excited to dose the first NAION patient in our ongoing clinical study of QPI-1007, which has demonstrated significant neuroprotective activity in preclinical studies."

About the Phase I Study

The Phase I, open-label, dose-escalation study will assess the safety, tolerability, and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II).  The study is expected to enroll up to 66 patients to receive a single intravitreal injection of QPI-1007 at varying doses with assessments of safety and tolerability for 12 months post-injection.  Secondary outcome measures include describing any anatomical changes in the optic nerve h
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical ... unique technology to deter prescription drug abuse today ... Anthony Soscia , has been chosen as ... ,s Health-Care Heroes Awards. The awards are presented ... to honor individuals and organizations demonstrating excellence and deserving ...
(Date:5/20/2013)... SAN DIEGO , May 20, 2013 ... in Elcelyx Therapeutics, Phase 2b dose-finding clinical trial of ... generic metformin, the foundational treatment for Type 2 diabetes. ... the multicenter U.S. program in June. Results of the ... are expected in late summer, and the read-out for ...
(Date:5/20/2013)... , May 20, 2013  Neuralstem, Inc. (NYSE ... , MD, PhD, principal investigator, presented updated Phase ... cell (NSI-566) trial in the treatment of amyotrophic lateral ... disease) at the neuro diabetes special medical symposium in ... a talk called "Recent Therapeutic Advances in Stem Cell ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... 20, 2011 TheCarrot.com , a leading ... programs, announced the immediate availability of its new ... the University of California at San Francisco,s Smoking ... behavior modification methodology with TheCarrot.com,s award-winning online and ...
... BETHESDA, Md., Jan. 20, 2011 Spherix Incorporated ... biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; ... food, supplement, biotechnology and pharmaceutical companies, today announced that ... million of shares of its common stock and warrants ...
Cached Medicine Technology:TheCarrot.com Launches Quit Smoking Program 2TheCarrot.com Launches Quit Smoking Program 3Spherix Announces Registered Direct Offering of $2.77 Million 2Spherix Announces Registered Direct Offering of $2.77 Million 3
(Date:5/20/2013)... May 20, 2013 This summer, digital ... world will make the pilgrimage to San Diego, CA, ... Digital Health Summer Summit produced by Living ... unique forum to showcase the latest digital health innovations, ... and network with some of industry’s most brilliant thinkers ...
(Date:5/20/2013)... Dennis Thompson HealthDay Reporter , , MONDAY, May ... attention deficit-hyperactivity disorder (ADHD) are twice as likely to ... disorder when they were young, a new 30-year study ... tended to have a higher body-mass index (BMI) and ... the disorder. Socioeconomics made no difference; well-off or ...
(Date:5/20/2013)... Posterior fossa subdural hematoma (PFSDH) is a serious and ... But with appropriate treatment, there,s an excellent chance of ... reports a study in the May issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , The results ...
(Date:5/20/2013)... Wolters Kluwer Health is pleased to announce ... journals won 13 ASHPE awards in 10 categories. ... publications for editorial, design, print and online award ... recognized year after year for delivering high-quality publications ... quality, depth, and impact," said Jayne Marks, Vice ...
(Date:5/20/2013)... Francisco, CA (PRWEB) May 20, 2013 ... health assistant at HealthBeat 2013. A mobile application called ... the time and effort it takes to arrange for ... Allie offers a unique combination of mobile technology and ... order to help people ensure their health care needs ...
Breaking Medicine News(10 mins):Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2Health News:Allayo Debuts Virtual Health Assistant At HealthBeat 2013 2
... Nutrisystem, Inc. (Nasdaq: NTRI ), a leading developer ... new multi-year alliance with the American Diabetes Association to ... public about the importance of weight loss for people ... Nutrisystem will support the Association,s efforts to fund both ...
... 26 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has ... change for the Company on the OTCBB will take place ... The new ticker symbol for "CardioGenics Holdings Inc." on ... the name and ticker symbol change that is scheduled to ...
... , WASHINGTON , Oct. 26 ... Karen Ignagni, President and CEO: , "A new government-run plan would ... down costs and improve quality. The American people want health ... that. , "The divisive debate about a government-run plan ...
... LAKE FOREST, Ill., Oct. 26 Akorn, Inc. (Nasdaq: AKRX ) will release third ... conference call on Tuesday, November 10, to discuss quarterly results followed by a Q&A session: , ... Akorn Third Quarter 2009 Conference Call, Date/Time: ... ...
... the impact of severe physical, psychosocial suffering, researchers say ... survivors of World War II, those who were potentially ... cancer, likely due to physical and mental stress, an ... compared cancer rates in more than 300,000 Israeli Jews ...
... spell trouble, study finds , MONDAY, Oct. 26 (HealthDay News) ... the risk of dangerous blood clots in veins, although that ... indicates. , The 10-year study found that bigger hips are ... women but not men, while a wider waistline was associated ...
Cached Medicine News:Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 2Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 3Health News:AHIP Statement on Government-Run Plan 2Health News:AHIP Statement on Government-Run Plan 3Health News:Exposure to Holocaust May Have Raised Cancer Risks 2Health News:Where You Put on Pounds May Influence Clot Risk 2
... CCR Medical's Articulating Tip Laryngoscopes ... in the Industry. The articulating ... by providing an improved view ... and Fiber Optic styles. We ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
... Medical's Articulating Tip Laryngoscopes are ... the Industry. The articulating tip ... providing an improved view of ... Fiber Optic styles. We guarantee ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: